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Introduction: Mantle cell lymphoma is one of the several subtypes of non-Hodgkin’s lymphoma. Mantle cell
lymphoma is the rarest of the subtypes, accounting for about 6% of all non-Hodgkin’s lymphoma cases in the
United States and Europe. Lymphoid neoplasms of the urinary tract and male genital organs are relatively rare,
accounting for less than 5% of extranodal lymphomas. We present a rare case of mantle cell lymphoma infiltrating
the ureter causing pelvi-ureteric junction obstruction on tissue diagnosis.
Case presentation: A 78-year-old Caucasian woman was referred to our department with right flank pain, pyrexia
and features of a urinary tract infection. A nephrostogram revealed a grossly distended right pelvicalyceal system in
a pelvi-ureteric junction obstruction pattern. She underwent an elective pyeloplasty after her acute management
and the results of histological examination revealed mantle cell lymphoma.
Conclusion: We describe a rare presentation of mantle cell lymphoma as a pelvi-ureteric junction obstruction. To
the best of our knowledge, there has not been any previously published report of the above finding. Our patient
had a history of a previous lymphoma but the aim of this manuscript is to highlight a possible presentation rather
than determining whether the mantle cell lymphoma was de novo or a transformation from her previous splenic
lymphoma with villous lymphocytes.Introduction
Mantle cell lymphoma (MCL) is one of the several sub-
types of non-Hodgkin’s lymphoma. MCL is the rarest of
the subtypes, accounting for about 6% of all non-
Hodgkin’s lymphoma cases in the United States and
Europe. It is the result of a malignant transformation of
a B lymphocyte in the outer edge of a lymph node
follicle, called the mantle zone. Those cells can spread
through the lymphatics and blood to other lymph nodes
or tissues such as the bone marrow, liver and gastro-
intestinal tract. MCL has the worst prognosis among
lymphomas, with a median survival of approximately
three to four years [1,2].
Lymphoid neoplasms of the urinary tract and male
genital organs are relatively rare, accounting for less
than 5% of extranodal lymphomas. We conducted a lit-
erature search of PubMed and MEDLINE using the key-
words ‘ureter’, ‘mantle cell lymphoma’ and ‘lymphoma’.
We found no reports of MCL involving the ureter.* Correspondence: n.ishvar@gmail.com
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reproduction in any medium, provided the orWe present a rare case of MCL infiltrating the ureter
causing pelvi-ureteric junction obstruction (PUJO) on
tissue diagnosis.Case presentation
A 78-year-old Caucasian woman was referred to our de-
partment with right flank pain, pyrexia and features of a
urinary tract infection. Part of her investigations in-
cluded an emergency ultrasound scan. This suggested
right hydronephrosis with debris, suggestive of infective
material, but with no obvious obstruction, mass or cal-
culi seen. In terms of her past medical history, she had a
splenectomy 15 years ago for splenic lymphoma with vil-
lous lymphocytes (SLVL), and had undergone laparo-
scopic cholecystectomy, a left total hip replacement and
hysterectomy. She had been under regular follow-up by
the hematologists and been managed conservatively. Part
of her follow-up with the hematologist included ultra-
sound and computed tomography scans, which suggestedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Ultrasound demonstrating hydronephrosis.
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nodes in her porta hepatis (Figures 1 and 2).
On the evening of admission, our patient underwent a
right nephrostomy insertion under imaging guidance in
view of the findings on her repeat ultrasound (Figure 3).
Results of her biochemical studies reported a white
blood cell count of 32.7×109 cells/L, C-reactive protein
level of 202mg/L and a creatinine level of 113μmol/L
(with a baseline of 60μmol/L) (Table 1). We drainedFigure 2 Ultrasound with hydronephrosis and dilated pelvis.bloody urine full of pus that grew coliform bacteria,
which we treated with intravenous antibiotics.
Over the next few days, our patient recovered quite well
and was discharged from hospital after a five-day stay.
In terms of her outpatient investigations, she underwent
a dimercaptosuccinic acid renogram, which showed
52% function in her right kidney and 48% in her left.
A nephrostogram revealed a grossly distended right
pelvicalyceal system in a PUJO pattern. The contrast passed
Figure 3 Persisting hydronephrosis on ultrasound with debris.
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der with just a little hold up over her iliac vessels (Figure 4).
Our patient underwent an elective laparoscopic pyeloplasty
two months after being discharged. The procedure
included a cystoscopy, which revealed an inflamed
bladder wall with normal ureteric orifices, and a right
retrograde that showed a normal ureter with narrowing
and a kink at the right pelvi-ureteric junction, with
contrast spill into her pelvis - typical of a PUJO. The
pyeloplasty was uneventful and her 6Fr stent was re-
moved at flexible cystoscopy four weeks after the
operation.
Histology of the specimen showed a dilated ureter
with loss of surface urothelium in many areas. The sub-
mucosa, muscle and deeper tissues contained a patchy
but heavy infiltrate of small lymphoid cells without any
follicular structures. These cells showed widespread
positivity for B-cell markers cluster of differentiation
(CD) 20 and CD79a, staining with markers B-cell lymph-
oma 2 and cyclin D2, weaker diffuse staining with CD5Figure 4 Nephrostogram showing the pelvi-ureteric
junction obstruction pattern.
Table 1 Laboratory investigations
Day 0 Day 5 (Discharge)
Hemoglobin (g/dL) 12.6 11.7
White blood cell count (×109/L) 32.7 14.3
Neutrophils (×109/L) 20.9 5.3
Creatinine (μmol/L) 113 64
C-reactive protein (mg/L) 202 107
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marker Ki67. These features are consistent with MCL
(Figure 5). A recent computed tomography scan sug-
gested persistence of her minor lymphadenopathy and
continuing appearance of the right PUJO (Figure 6). An
intravenous urogram was performed, with both kidneys
concentrating contrast appropriately, with a pelvicalyceal
system that was prominent on the right and evidence of
appropriate drainage bilaterally.
Our patient has now been referred back to the hematologist
for further management of her MCL and is undergoing
rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone chemotherapy treatment.Discussion
Lymphomas in the genitourinary tract are extremely rare,
only a handful of small case series and isolated reports
have been published describing their predominant sites
and subtypes [3]. To the best of our knowledge, lymph-
oma infiltrating the ureter has only been mentioned byFigure 5 Histology slides: Mantle cell lymphoma, CD20, CyclinD and CSchniederjan and Osunkoya in their case series [4]. MCL
involving the ureter has not been described before.
MCL is a subtype of B-cell lymphoma, derived from
CD5-positive antigen-naïve pregerminal center B-cells
within the mantle zone that surrounds normal germinal
center follicles. MCL cells generally over-express cyclin
D1 due to a t(11:14) chromosomal translocation in
the deoxyribonucleic acid (DNA). The cause is unknown
and no inherited predisposition has been identified [5].
Ki-67 is an indicator of how fast cells mature: the
lower the percentage, the lower the speed of maturity,
and the more indolent the disease. In our scenario, our
patient expressed less than 5% staining [6].
She had previously been diagnosed with SLVL, after
which she had a splenectomy. Unfortunately, it was un-
clear how this diagnosis was made. She had been asymp-
tomatic until her admission for pyonephrosis and follow-
up scans after her splenectomy attributed her right
hydronephrosis to a ‘congenital’ PUJO.
With good renal function demonstrated on her
dimercaptosuccinic acid scan and her history of SLVL,D5 staining.
Figure 6 Computed tomography scan with persisting right PUJO and minor lymphadenopathy.
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congenital condition.
SLVL is a lymphoproliferative disorder characterized by
the presence in the peripheral blood of atypical B-
lymphocytes. Clinical features include massive splenomegaly
and absence of peripheral lymphadenopathy. In our patient,
an incidental finding of splenomegaly led to her having a
splenectomy for SLVL [7].
In retrospect, we could argue that with good renal func-
tion on her previous imaging and with her history of
SLVL, her right-sided hydronephrosis was secondary to
the lymphoma process rather than to a congenital finding.Conclusion
We describe a rare presentation of MCL as a PUJO. To
the best of our knowledge, there has not been any previ-
ously published report of the above finding. Our patient
had a history of a previous lymphoma but the aim of this
manuscript was to highlight a possible presentation ra-
ther than determining whether the MCL was de novo or
a transformation from her previous SLVL.Consent
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